Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

A Multi-center,_double-blind,_pararel-group Comparison Trial to Investigate the Effect of Short-term Administration of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients (Phase_4 Study)

One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the morning for up to 14 days to heart failure patients with volume overload that does not show adequate response to other diuretics such as loop diuretics in order to investigate the effect of tolvaptan on the mid- to long-term prognosis of the target population. The efficacy of tolvaptan during the treatment period will also be investigated.

Study Overview

• Status: Completed
• Conditions: Heart Failure
• Intervention / Treatment: Drug: Tolvaptan; Drug: Placebo of tolvaptan

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• Japan
  • Chube Region, Japan
  • Chushikoku Region, Japan
  • Hokkaido Region, Japan
  • Hokuriku Region, Japan
  • Kansai Region, Japan
  • Kanto Region, Japan
  • Kyushu Region, Japan
  • Tohoku Region, Japan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients from whom informed consent has been properly obtained in writing prior to start of the trial
• Patients who have been clinically diagnosed with heart failure
• Patients with any of the following conditions or symptoms: lower limb edema, dyspnea, jugular venous distension, hepatomegaly, pulmonary rales, third heart sound, or pulmonary congestion
• Patients who have been receiving loop diuretics, thiazide diuretics, or anti-aldosterone diuretics
• Male or female patients of age 20 to 85 years inclusive (at time of informed consent)
• Patients who, together with their partner(s), are able to use an appropriate method of contraception until 3 months after final trial drug administration
• Patients who are able to be hospitalized at the trial site for at least 7 days from the start of trial drug administration

Exclusion Criteria:

• Patients with a history of hypersensitivity to any ingredient of the drug or to tolvaptan analogues (e.g., mozavaptan hydrochloride)
• Patients with anuria
• Patients who cannot sense thirst or who have difficulty with fluid intake
• Patients with hypernatremia (serum sodium concentration > institutional upper limit of normal) 5) Female patients who are pregnant, possibly pregnant, or nursing

• Patients judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial due to any of the following conditions or symptoms:

  • Hyponatremia (serum sodium concentration < 125 mEq/L)
  • Serious coronary artery disease or cerebrovascular disease
  • Hyperkalemia
  • Severe renal disorder
  • Poorly controlled diabetes mellitus
  • Severe hepatic disease
  • Impaired urinary excretion due to urinary stenosis, calculus, or tumor
  • Cardiac valve disease with significant heart valve stenosis
  • Malignant tumor of unfavorable prognosis
• Patients with suspected hypovolemia
• Patients with an implanted circulatory support device
• Patients in whom acute cardiac infarction occurred within 30 days prior to the screening examination
• Patients who participated in any other clinical trial or postmarketing clinical trial within 30 days prior to the date of informed consent for the present trial
• Patients who received tolvaptan within 26 weeks prior to the date of informed consent
• Patients who are otherwise judged by the investigator or sub-investigator to be inappropriate for inclusion in the trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo of tolvaptan; Once-daily oral administration of one placebo tablet in the morning
Experimental: Tolvaptan; 15 mg	Drug: Tolvaptan; Once-daily oral administration of one tolvaptan 15 mg tablet in the morning

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cummulative Incidence of Events at Week 26	From start day of IMP administration to final day of follow up period, 1) and 2) below were defined as event; Death from cardiovascular events; Worsening of heart failureThe day of re-hospitalization due to worsening of heart failureThe day of medication below due to worsening of heart failure Phosphodiesterase III inhibitors (Injection), Catecholamine preparations (Injection), Colforsin preparations (Injection), Diuretics (Injection), Human atrial natriuretic peptide preparations (Injection)：Calperitide (Injection)	Week 26
Mortality （Number of Death）	Statistical comparison was not done.	Week26
Body Weight	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Number of Subjects Whose Lower Limb Edema Severity Grading Improved by One or More Grade	Of the subjects who had lower limb edema at baseline, the number of subjects whose lower limb edema severity grading. Statistical comparison was not done.	Day15
Jugular Venous Distension	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Change in Liver Size From Baseline	The comparison of the average of amount of change from baseline. Statistical comparison was not done．	Day15
Pulmonary Rales	Of the subjects who had pulmonary rales at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Third Heart Sound	Of the subjects who had third heart sound at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Cardiothoracic Ratio	Investigator majored Thoracic length and Cardiac length from chest X-ray. Cardiothoracic Ratio was calculated from Cardiac length/Thoracic length*100. Lowering of Cardiothoracic Ratio suggests recovery from heart congestion. The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Pulmonary Congestion	Of the subjects who had pulmonary congestion at baseline, the number of subjects whose pulmonary congestion severity grading showed an improvement of one grade or more (eg, moderate to mild) at completion of treatment. Statistical comparison was not done.	Day15
Plasma Brain Natriuretic Peptide (BNP) Concentration	The comparison of the average of amount of change from baseline. Statistical comparison was not done.	Day15
Dypnea	Of the subjects who had dyspnoea at baseline, the number of subjects whose symptom was resolved at completion of treatment. Statistical comparison was not done.	Day15
Number of Subjects Whose New York Heart Association (NYHA) Classification Improved by One More Grade From Baseline	New York Heart Association (NYHA) Classification is below ClassI：No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). ClassII：Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath). ClassIII：Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. ClassIV：Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.	The day after last IMP administration and Baseline

Collaborators and Investigators

• Sponsor: Otsuka Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start: September 1, 2011
• Primary Completion (Actual): March 1, 2014
• Study Completion (Actual): March 1, 2014

Study Registration Dates

• First Submitted: September 15, 2011
• First Submitted That Met QC Criteria: September 21, 2011
• First Posted (Estimate): September 22, 2011

Study Record Updates

• Last Update Posted (Actual): October 22, 2019
• Last Update Submitted That Met QC Criteria: October 3, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Keywords: Heart failure; Volume overload; Tolvaptan; loop diuretics
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Natriuretic Agents; Antidiuretic Hormone Receptor Antagonists; Tolvaptan
• Other Study ID Numbers: 156-10-005; JapicCTI-111621 (Other Identifier: JAPIC)